Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a new study suggests that it might take a while for us to get there. The ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

Tencent Hy4 preview uses a recursive self-improvement loop that boosted its own inference throughput by 31.8%. The ...

Anthropic executives Eric Kauderer-Abrams and Jonathan “JP” Pelosi explain how Claude is moving beyond AI assistants into ...

The study says AI use is spreading across the drug-development process and tracks strategies among pharma groups, AI ventures ...

Anthropic's latest research showcases automated systems enhancing AI alignment benchmarks, achieving consistent improvements ...

Gemini 4 and OpenAI Astra test internal boundaries while Ilya Sutskever's speculated SSI model secures NVIDIA funding to ...

It’s clear here in Silicon Valley that AI is advancing faster than humans’ ability to control it. That means even sober prophecies seem optimistic, says Guardian columnist Timothy Garton Ash ...

AI is approaching the limits of human-generated training data. Explore model collapse, synthetic data, and why preserving ...

The tech industry is realizing it needs to build agents based on what regular consumers want, not just what its AI models can do.

A new generation of philanthropists made rich by artificial intelligence are preparing to give away their vast wealth. What should we make of a multi-billion-dollar pinky promise?